applications for ooplasmic transplantation jacques cohen brmac, 2002
TRANSCRIPT
![Page 1: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/1.jpg)
Applications for Ooplasmic Transplantation
Jacques CohenBRMAC, 2002
![Page 2: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/2.jpg)
Oocyte DeficitsOocyte Deficits• Aneuploidy Aneuploidy
• Chromosome breakageChromosome breakage
• Gene dysfunctionGene dysfunction
• Genomic activation delayedGenomic activation delayed
![Page 3: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/3.jpg)
Implantation
40%
10%
20%
30%
20-34 35-39 40-45
Maternal age
Aneuploidy
Munne et al, 1995
![Page 4: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/4.jpg)
Implantation Rate After Aneuploidy Testing
0
10
20
30
40
50
60
28-31 31-34 34-37 37-40 40-44
Maternal Age
%
![Page 5: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/5.jpg)
Is there evidence of an ooplasmic deficit?
![Page 6: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/6.jpg)
I II III
I II III
Alikani et al, 1995, 1999
CELLULAR FRAGMENTATION
![Page 7: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/7.jpg)
IV V
IV
IV V
Alikani et al, 1995, 1999
![Page 8: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/8.jpg)
PED Gene
![Page 9: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/9.jpg)
Ped Gene Phenotype in HumanPed Gene Phenotype in Human(n=1360)
Development Implantation=< 7-cells 17.4%=> 8-cells 30.3%
P<0.001
Warner et al, 1998
![Page 10: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/10.jpg)
9aa peptide
Outside the cell
Inside the cell
Predicted protein characteristics of the Ped fast and Ped slow phenotype (mouse)
No Qa-2 proteinQa-2 protein
Ped slowSlow embryosmorula stage-19 cellsAbsence of protein
Ped fastFast embryosblastocyst stage-32 cellsPresence of protein
Cell membrane
Warner et al, 1998
![Page 11: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/11.jpg)
Mad2 mRNA Concentration in Human Oocytes versus Maternal Age
Maternal Age
Co
nce
ntr
atio
n (
100
s)
P<.001P<.001P<.001
![Page 12: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/12.jpg)
Mitochondria Genes
![Page 13: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/13.jpg)
IQM
ND1
MELAS
Sporadic myopathy
ND2
W A N C Y
OL
COXI S D
COXII K
A8/6
MERFF
Sporadic myopathy
Sporadic myopathy
COXIII
G
ND3
R
ND4L
ND4
LSH
ND5
ND6
Cyt b
E
OH
HSP
LSP
Sporadic myopathy
![Page 14: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/14.jpg)
0
10
20
30
40
50
60
Any mtDNArearrangement
Multiplerearrangements
OocyteEmbryo
23 rearrangements
P<0.0001N=702 Barritt et al, 1999
![Page 15: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/15.jpg)
mtDNA Mutation T414G and Age
Barritt et al., Reproductive Biomedicine Online, 2001
![Page 16: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/16.jpg)
0
10
20
30
40
24-36 years 37-42P<0.01N=66 Barritt et al, Reprod. BioMed. Online, 2001
MtDNA Point Mutation (T414G) in Replication Control Region of Compromised Human Oocytes
![Page 17: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/17.jpg)
Clinical RationaleClinical Rationale
• Knowledge base for specific Knowledge base for specific
ooplasmic defect treatment ooplasmic defect treatment
does not existdoes not exist• Are all mRNA, proteins, Are all mRNA, proteins,
mitochondria the same?mitochondria the same?
![Page 18: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/18.jpg)
Animal Experimentation and Cytoplasmic Transplantation
![Page 19: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/19.jpg)
• Cyto-Transfer Using Cytochalasin in Outbred MiceCyto-Transfer Using Cytochalasin in Outbred Mice (Muggleton-Harris et al, 1982,1988)(Muggleton-Harris et al, 1982,1988)
• Cytoplasmic Replacement Using Karyoplasts -AsynchronyCytoplasmic Replacement Using Karyoplasts -Asynchrony(McGrath and Solter, 1983; Surani 80’s – 00’s; Willadsen, 1986; Zhang et (McGrath and Solter, 1983; Surani 80’s – 00’s; Willadsen, 1986; Zhang et
al, 2000; Takumi et al, 2001)al, 2000; Takumi et al, 2001)
• Cytoplasmic Transfer in Mouse, Monkey, HumanCytoplasmic Transfer in Mouse, Monkey, Human(Flood et al, 1990; Smith et al, 1991: Levron et al, 1996; Jenuth et (Flood et al, 1990; Smith et al, 1991: Levron et al, 1996; Jenuth et
al, 1996; Meirelles and Smith, 1997, 1998; Van Blerkom et al, al, 1996; Meirelles and Smith, 1997, 1998; Van Blerkom et al, 1998; Cohen et al, 1997, 1998; Takeda et al, 1998)1998; Cohen et al, 1997, 1998; Takeda et al, 1998)
• Cybrids in mouse and primates Cybrids in mouse and primates (Kenyon and Moraes, 1997; Yamaoka et al, 2000)(Kenyon and Moraes, 1997; Yamaoka et al, 2000)
Cytoplasmic Transfer ExperimentationCytoplasmic Transfer Experimentation
![Page 20: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/20.jpg)
LC Smith Lab: Heteroplasmic Mammals after Manipulation of Cytoplasm in Early Embryos
Healthy, normal mice produced following Healthy, normal mice produced following karyoplast and cytoplast transfer between inbred karyoplast and cytoplast transfer between inbred mouse strains w/ differing mitochondrial mouse strains w/ differing mitochondrial backgroundsbackgrounds
Hundreds of such heteroplasmic animals have been Hundreds of such heteroplasmic animals have been produced and bred over produced and bred over 15 generations15 generations with no with no developmental or health problemsdevelopmental or health problems
![Page 21: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/21.jpg)
Levron et al (1996) : Cytoplast transfer across early developmental stages in mouse eggs/embryos (F1 Hybrid)
The transfer of cytoplasm between mature The transfer of cytoplasm between mature mouse oocytes and zygotes led to development mouse oocytes and zygotes led to development that was identical with controls.that was identical with controls.
Following embryo transfers – implantation Following embryo transfers – implantation and viability of such cyto-transfer embryos and viability of such cyto-transfer embryos was in one scenario was in one scenario significantly improvedsignificantly improved over controls. over controls.
![Page 22: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/22.jpg)
Cybrid ExperimentsCybrid ExperimentsCreation of cell hybrids w/ disparate nuclear Creation of cell hybrids w/ disparate nuclear and and Mitochondrial makeup – cross species/genusMitochondrial makeup – cross species/genus
Normal mitochondrial function in many Normal mitochondrial function in many
scenariosscenarios
![Page 23: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/23.jpg)
Nuclear transplantation of F1 hybrid mouse zygotes
Malter and Schimmel, unpublished
![Page 24: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/24.jpg)
Cytoplasmic Transfer in Mouse Cytoplasmic Transfer in Mouse Zygote Using Karyoplast FusionZygote Using Karyoplast Fusion
• 12 mice – (F1 hybrids)12 mice – (F1 hybrids)• No apparent problemsNo apparent problems• First generation 30 months oldFirst generation 30 months old• One more generation (n=13) One more generation (n=13) • No apparent problemsNo apparent problems
![Page 25: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/25.jpg)
NZB oocyte
CB6F1 cytoplasm
Ooplasmic Transplantation By Piezo Facilitated Injection
• Thinned tool• Multiple donor aspiration• Similar ratio to human procedure
![Page 26: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/26.jpg)
Survival – up to 90+ %
Good preimplantation development
![Page 27: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/27.jpg)
Clinical ExperienceClinical Experience
![Page 28: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/28.jpg)
Informed ConsentInformed Consent
• First IRB 1995First IRB 1995• Second IRB 1999Second IRB 1999• Third IRB pendingThird IRB pending
![Page 29: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/29.jpg)
Normal donor stage
Compromised recipient stage
![Page 30: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/30.jpg)
RecipientDonor
Ooplasmic donation by injection
![Page 31: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/31.jpg)
![Page 32: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/32.jpg)
Ooplasmic Transfer Ooplasmic Transfer by injectionby injection
• 28 patients (33 cycles): egg donation 28 patients (33 cycles): egg donation candidatescandidates
• Recurrent implantation failure (RIF)Recurrent implantation failure (RIF)• Recurrent poor embryo morphologyRecurrent poor embryo morphology• 9 male factors9 male factors• 5 with repeated miscarriages5 with repeated miscarriages
June 2001June 2001
![Page 33: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/33.jpg)
• 33 attempts• 28 couples• 31 transfers• 13 clinical pregnancies• 2 biochemical• 1 first tri miscarriage (XO)• 1 twin with XO (IRB - 1999)
Barritt et al, 2000 Hum Reprod 15,2:207
![Page 34: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/34.jpg)
• one twin born• one quadruplet born• 17 babies• pediatric follow-up • one PDD-NOS (18 month)
![Page 35: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/35.jpg)
0
10
20
30
40
50
60
70
Clinical Pregnancy FHB / embryo
123454.8
Cycle Attempts
Ooplasmic transfer cases
n=2477n=8487
![Page 36: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/36.jpg)
![Page 37: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/37.jpg)
10µm
30µm
a
10µm
Barritt et al, 2001
![Page 38: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/38.jpg)
![Page 39: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/39.jpg)
DNA Sequencing
mtDNA Sequence Analysis of Hyper-variable Region
![Page 40: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/40.jpg)
• ‘spare’ embryos 17/35 • amniocentesis 3/10• placenta 3/13• fetal blood 3/13• Babies tested 2/13
Incidence of “Heteroplasmy”
![Page 41: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/41.jpg)
Molecular Beacon for Recipient 16224 mt
DNA
![Page 42: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/42.jpg)
““Germ-line Genetic Modification”Germ-line Genetic Modification”
Barritt et al, 2001Barritt et al, 2001
![Page 43: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/43.jpg)
Tully et al, 2000Wilson et al, 1997
Mitochondrial diversity in the hyper-variable area occurs in 10-
15% of ‘normal’ humans
![Page 44: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/44.jpg)
Hyper-variable area is in a non-coding region
![Page 45: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/45.jpg)
No known cases of mitochondrial disease
after…….egg donation
![Page 46: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/46.jpg)
Risk To Offspring:Risk To Offspring:1.1.Mechanical Damage?Mechanical Damage?
• ICSI-derived procedure• CTr Survival >90%• CTr Fertilization >65%• > 100,000 babies with ICSI• Preimplantation like IVF• Malformation rate like IVF
![Page 47: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/47.jpg)
Risk To Offspring:Risk To Offspring:
2. Inadvertent Transfer?2. Inadvertent Transfer?
• Unique organelles• Avoid spindle• Cytogenetic analysis• Detailed study of zygote• Centriole is sperm derived
![Page 48: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/48.jpg)
Risk To Offspring:Risk To Offspring:
3. Enhanced survival?3. Enhanced survival?
• Aneuploidy is common• Enhanced in ICSI?• XO most common
![Page 49: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/49.jpg)
Risk To Offspring:Risk To Offspring:
4. Heteroplasmy?4. Heteroplasmy?
• Three polymorphisms confirmed• Heteroplasmic polymorphisms common in population• Very common in experimental embryology• No evidence of risk between outbred individuals in same species
![Page 50: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/50.jpg)
Risk To Mother:Risk To Mother:
Elevated Incidence of Elevated Incidence of Chromosomal Anomalies?Chromosomal Anomalies?
• No statistical evidence for this• Aneuploidy most common form of miscarriage (>60%)• XO most common form of aneuploidy
![Page 51: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/51.jpg)
What Cellular Issues?What Cellular Issues?• Donor Screening?Donor Screening?• Abnormal Zygotes?Abnormal Zygotes?• Source of MitochondriaSource of Mitochondria• Video For EvidenceVideo For Evidence• Frozen oocytes?Frozen oocytes?• Chromosome screenChromosome screen• Screen embryos?Screen embryos?
![Page 52: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/52.jpg)
Further Non-clinical Further Non-clinical ExperimentationExperimentation
• Mouse model: profound genetic Mouse model: profound genetic
and functional differencesand functional differences• Primate model?Primate model?• Costs?Costs?
![Page 53: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/53.jpg)
Possible Clinical Possible Clinical Applications for Applications for Cytoplasmic Transfer:Cytoplasmic Transfer:
• Treating other groups with RIFTreating other groups with RIF• Avoiding AneuploidyAvoiding Aneuploidy• Egg FreezingEgg Freezing• Diagnosing Sperm DysfunctionDiagnosing Sperm Dysfunction• Treating Mitochondrial DiseaseTreating Mitochondrial Disease• HaploidizationHaploidization
![Page 54: Applications for Ooplasmic Transplantation Jacques Cohen BRMAC, 2002](https://reader034.vdocuments.site/reader034/viewer/2022052509/56649d0b5503460f949de34b/html5/thumbnails/54.jpg)
Mitochondria infusionMitochondria infusion (Tzeng et al, 2001)(Tzeng et al, 2001)
• Argues there is a single causeArgues there is a single cause• Somatic mitochondriaSomatic mitochondria• Isolation process?Isolation process?• Age-related mutationsAge-related mutations• ReplicationReplication• Multiple mtDNA genomesMultiple mtDNA genomes